<div class="table-wrap table anchored whole_rhythm" id="T1">
<h3>Table 1</h3>
<!--caption a7--><div class="caption"><p id="__p21">Baseline demographic and clinical characteristics</p></div>
<div data-largeobj="" data-largeobj-link-rid="largeobj_idm140421408263888" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table">
<thead>
<tr>
<td rowspan="2" colspan="1" valign="bottom" align="left"></td>
<td colspan="2" rowspan="1" valign="bottom" align="left">Normal baseline CRP<br>(&lt;5 mg/L)</td>
<td colspan="2" rowspan="1" valign="bottom" align="left">Elevated baseline CRP<br>(≥5 mg/L)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="bottom" align="left">Pooled secukinumab<br>150 mg (N=72)</td>
<td rowspan="1" colspan="1" valign="bottom" align="left">Pooled placebo<br>(N=71)</td>
<td rowspan="1" colspan="1" valign="bottom" align="left">Pooled secukinumab<br>150 mg (N=125)</td>
<td rowspan="1" colspan="1" valign="bottom" align="left">Pooled placebo<br>(N=124)</td>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Age (years), mean (SD)</td>
<td rowspan="1" colspan="1" valign="top" align="center">42.3 (10.5)</td>
<td rowspan="1" colspan="1" valign="top" align="center">45.3 (13.2)</td>
<td rowspan="1" colspan="1" valign="top" align="center">39.9 (12.7)</td>
<td rowspan="1" colspan="1" valign="top" align="center">42.2 (12.3)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Male, n (%)</td>
<td rowspan="1" colspan="1" valign="top" align="center">39 (54.2)</td>
<td rowspan="1" colspan="1" valign="top" align="center">47 (66.2)</td>
<td rowspan="1" colspan="1" valign="top" align="center">91 (72.8)</td>
<td rowspan="1" colspan="1" valign="top" align="center">93 (75.0)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Weight (kg), mean (SD)</td>
<td rowspan="1" colspan="1" valign="top" align="center">74.5 (14.6)</td>
<td rowspan="1" colspan="1" valign="top" align="center">76.4 (13.8)</td>
<td rowspan="1" colspan="1" valign="top" align="center">79.2 (18.4)</td>
<td rowspan="1" colspan="1" valign="top" align="center">79.0 (15.3)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Caucasian, n (%)<strong>*</strong>
</td>
<td rowspan="1" colspan="1" valign="top" align="center">50 (69.4)</td>
<td rowspan="1" colspan="1" valign="top" align="center">51 (71.8)</td>
<td rowspan="1" colspan="1" valign="top" align="center">88 (70.4)</td>
<td rowspan="1" colspan="1" valign="top" align="center">100 (80.6)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Time since AS diagnosis (years), mean (SD)</td>
<td rowspan="1" colspan="1" valign="top" align="center">5.9 (7.2)</td>
<td rowspan="1" colspan="1" valign="top" align="center">8.1 (9.9)</td>
<td rowspan="1" colspan="1" valign="top" align="center">7.2 (7.5)</td>
<td rowspan="1" colspan="1" valign="top" align="center">7.3 (8.3)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Positive for HLA-B27, n (%)</td>
<td rowspan="1" colspan="1" valign="top" align="center">44 (61.1)</td>
<td rowspan="1" colspan="1" valign="top" align="center">53 (74.6)</td>
<td rowspan="1" colspan="1" valign="top" align="center">99 (79.2)</td>
<td rowspan="1" colspan="1" valign="top" align="center">95 (76.6)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">TNFi-naïve, n (%)</td>
<td rowspan="1" colspan="1" valign="top" align="center">52 (72.2)</td>
<td rowspan="1" colspan="1" valign="top" align="center">39 (54.9)</td>
<td rowspan="1" colspan="1" valign="top" align="center">84 (67.2)</td>
<td rowspan="1" colspan="1" valign="top" align="center">94 (75.8)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Concomitant methotrexate use, n (%)</td>
<td rowspan="1" colspan="1" valign="top" align="center">9 (12.5)</td>
<td rowspan="1" colspan="1" valign="top" align="center">7 (9.9)</td>
<td rowspan="1" colspan="1" valign="top" align="center">16 (12.8)</td>
<td rowspan="1" colspan="1" valign="top" align="center">17 (13.7)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">hsCRP (mg/L), median (minimum‒maximum)</td>
<td rowspan="1" colspan="1" valign="top" align="center">2.1 (0.2‒4.9)</td>
<td rowspan="1" colspan="1" valign="top" align="center">1.9 (0.2‒4.9)</td>
<td rowspan="1" colspan="1" valign="top" align="center">16.8 (5.0‒237.0)</td>
<td rowspan="1" colspan="1" valign="top" align="center">14.9 (5.0‒146.8)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Total BASDAI score, mean (SD)</td>
<td rowspan="1" colspan="1" valign="top" align="center">6.7 (1.4)</td>
<td rowspan="1" colspan="1" valign="top" align="center">6.6 (1.6)</td>
<td rowspan="1" colspan="1" valign="top" align="center">6.3 (1.6)</td>
<td rowspan="1" colspan="1" valign="top" align="center">6.6 (1.4)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">PtGA of disease activity (0‒100 mm), mean (SD)†</td>
<td rowspan="1" colspan="1" valign="top" align="center">68.0 (17.4)</td>
<td rowspan="1" colspan="1" valign="top" align="center">66.9 (19.3)</td>
<td rowspan="1" colspan="1" valign="top" align="center">63.7 (19.1)</td>
<td rowspan="1" colspan="1" valign="top" align="center">68.4 (16.7)</td>
</tr>
</tbody>
</table></div>
<div id="largeobj_idm140421408263888" class="largeobj-link align_right" style="display: none"><a target="object" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269637/table/T1/?report=objectonly">Open in a separate window</a></div>
<div class="tblwrap-foot">
<div id="T1_FN1"><p id="__p22" class="p p-first-last">*Race was self-assessed.</p></div>
<div id="T1_FN2"><p id="__p23" class="p p-first-last">†Disease activity was scored on a visual-analog scale from 0 (no disease activity) to 100 mm (the most severe disease activity).</p></div>
<div id="T1_FN3"><p id="__p24" class="p p-first-last">AS,
 ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease 
Activity Index; CRP, C-reactive protein; HLA, human leucocyte antigen; 
N, number of patients in this pooled study; PtGA, patients global 
assessment; TNFi, tumor necrosis factor inhibitor; hsCRP, high 
sensitivity CRP.</p></div>
</div>
</div>
